Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer

NCT02216786 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT02216786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02216786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Completed
Start date
January 16, 2014
Completion date
December 31, 2021
Enrollment
333 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive breast cancer